Lung Cancer Liquid Biopsy Market: as Guardant Health reporting USD 739.00 Million in FY2024 revenue at 22 to 24% growth and receiving FDA approval for Guardant360 Liquid CDx in May 2026 as the largest FDA-approved liquid biopsy panel with 100-fold wider genomic footprint integrating genomic and epigenomic data establishes the commercial and regulatory frontier of comprehensive blood-based NSCLC profiling, CMS establishing national payment rates of USD 5,000.00 for Guardant360 CDx and USD 3,500.00 each for FoundationOne Liquid CDx and Signatera in 2025 creates the uniform reimbursement certainty that accelerates community oncology test ordering above the prior fragmented local coverage determination framework, so ASCO 2024 living guideline and NCCN version 4.2024 both recommending comprehensive blood-based genomic profiling when tissue is inadequate expands the eligible NSCLC patient pool by an estimated 20 to 30%.

The global lung cancer liquid biopsy market size was USD 1.12 Billion in 2025 and is expected to register a revenue CAGR of 14.5% during the forecast period. Market revenue growth is driven by factors such as the FDA May 2026 approval of Guardant360 Liquid CDx as the largest FDA-approved liquid biopsy panel integrating genomic and epigenomic data with a 100-fold wider genomic footprint than the previously approved Guardant360 CDx establishing a new comprehensive profiling standard for blood-based NSCLC tumour characterisation, CMS 2025 national payment rates of USD 5,000.00 for Guardant360 CDx and USD 3,500.00 each for FoundationOne Liquid CDx and Signatera creating the uniform reimbursement certainty that eliminates the geographic access inequities and billing uncertainty of the prior local coverage determination framework, and as well as ASCO 2024 living guideline and NCCN version 4.2024 both formally endorsing comprehensive blood-based genomic profiling when tissue is inadequate for NSCLC genomic testing, expanding the eligible patient pool by an estimated 20 to 30% by creating a guideline-recommended indication across all tissue-inadequate NSCLC patients. The first driving factor is Guardant Health FY2024 total revenue of USD 739.00 Million per the company financial disclosures, representing 22 to 24% year-on-year growth, with Q2 2024 revenue growing 29% year-over-year per Guardant's SEC 8-K filed 7 August 2024, with Guardant360 CDx holding FDA approval as a companion diagnostic for osimertinib in EGFR-mutated NSCLC and the CMS establishing national coverage payment rates of USD 5,000.00 for Guardant360 CDx in 2025, creating a reimbursement framework that sustains commercial liquid biopsy test utilisation at oncology accounts without prior authorisation for companion diagnostic-indicated testing. Lung cancer liquid biopsy encompasses non-invasive blood-based tests detecting circulating tumour DNA, circulating tumour cells, exosomes, and other cancer-derived analytes to guide NSCLC treatment selection, monitor treatment response, detect resistance mutations, assess minimal residual disease after curative-intent surgery, and screen high-risk populations. The World Health Organization estimated approximately 2.20 Million new lung cancer cases and 1.80 Million lung cancer deaths occurring globally annually, with non-small cell lung cancer representing approximately 85% of incident cases and harbouring targetable oncogenic driver alterations including EGFR, ALK, ROS1, KRAS, MET, RET, and NTRK in approximately 60 to 70% of lung adenocarcinoma tumours amenable to liquid biopsy companion diagnostic testing. In May 2026, Guardant Health, United States, received FDA approval for Guardant360 Liquid CDx, described as the largest FDA-approved liquid biopsy panel, integrating genomic and epigenomic sequencing to deliver comprehensive tumour profiling from a single blood draw with a 100-fold wider genomic footprint than the previously approved Guardant360 CDx panel. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way ESMO 2024 consensus statements adding plasma testing for resistance mechanism identification after targeted therapy failure in NSCLC and the FDA November 2024 draft guidance establishing analytic validity thresholds for ctDNA minimal residual disease assays create two additional recurring liquid biopsy test demand channels above the initial therapy selection testing episode, which allows each NSCLC patient managed with targeted therapy to generate two to four additional liquid biopsy test orders during their treatment course rather than a single companion diagnostic test at diagnosis. Once a patient with EGFR-mutant NSCLC is initiated on osimertinib based on a Guardant360 CDx companion diagnostic result, ESMO-endorsed plasma resistance monitoring at progression generates a second Guardant360 CDx test order for T790M and C797S resistance mutation detection at treatment failure, and ctDNA MRD surveillance after resection generates serial blood draw test orders over the 2 to 5 year post-surgical surveillance period. As a result, the per-patient lifetime liquid biopsy test volume is compounding above the initial therapy selection episode, concentrating revenue around the platforms with the broadest companion diagnostic indication portfolios and the most established MRD surveillance clinical evidence, and the forecast tilts toward these multi-episode testing platforms rather than single-indication assays. For instance, in November 2023, Grail LLC received CE mark approval for its Galleri multi-cancer early detection blood test, one of several events expanding the lung cancer liquid biopsy commercial landscape in the 12 months to Q2 2026. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the reinforcing combination of a major FDA regulatory approval expanding the analytical capability frontier of blood-based NSCLC testing and the CMS policy decision establishing national payment rates that eliminate the geographic reimbursement fragmentation that had constrained community oncology test ordering under the prior local coverage determination framework. FDA approval and CMS reimbursement work together commercially because Guardant360 Liquid CDx FDA approval in May 2026 provides the clinical credibility and companion diagnostic indication coverage to justify oncologist ordering of comprehensive liquid biopsy testing, while the CMS USD 5,000.00 national payment rate provides the billing certainty that removes the financial risk from community oncology practices uncertain about reimbursement under local MAC coverage policies. Guardant Health FY2024 total revenue reached USD 739.00 Million at 22 to 24% growth per company financial disclosures, with Q2 2024 revenue growing 29% year-over-year per Guardant's SEC 8-K filed 7 August 2024, confirming that the commercial trajectory was already accelerating before the May 2026 Guardant360 Liquid CDx approval. The Guardant360 Liquid CDx approval creates a 100-fold wider genomic footprint than the previously approved Guardant360 CDx by integrating epigenomic sequencing to provide methylation-based cancer detection signal that is orthogonal to mutation-based ctDNA detection, improving sensitivity in early-stage and low-mutation-burden NSCLC scenarios where conventional ctDNA assays have their greatest analytical limitations. The SCRUM-Japan GOZILA study data published in Nature Medicine showed patients receiving Guardant360 CDx-guided treatment survived twice as long per Guardant's Q3 2024 SEC 8-K, providing international clinical evidence for comprehensive liquid biopsy clinical utility in lung cancer treatment outcomes that supports payer confidence in reimbursement maintenance. These are some of the key factors driving revenue growth of the market.

The second driver is the clinical guideline framework that formally endorses comprehensive liquid biopsy testing at multiple clinical decision points in the NSCLC treatment pathway rather than only for initial companion diagnostic indications, because guideline endorsement converts liquid biopsy ordering from a physician discretion decision at individual oncologist level into a clinical standard of care recommendation that drives systematic ordering protocols at oncology programme level. Guideline-driven demand works commercially because ASCO 2024 living guideline and NCCN version 4.2024 recommending comprehensive blood-based CGP when tissue is inadequate formally authorises ordering of Guardant360 CDx or FoundationOne Liquid CDx at diagnosis without requiring a specific drug companion diagnostic context, expanding the eligible patient pool by an estimated 20 to 30% per commercial analysis by including all tissue-inadequate NSCLC patients regardless of their specific targeted therapy eligibility. ESMO 2024 consensus statements adding plasma testing for resistance mechanism identification after targeted therapy failure reinforces payer confidence in European markets by establishing resistance testing as a recurring clinical standard that generates additional liquid biopsy test demand at NSCLC treatment progression timepoints. FDA November 2024 draft guidance establishing explicit analytic validity thresholds for ctDNA minimal residual disease assays catalyses investment in ultra-deep sequencing platforms for post-surgical NSCLC MRD detection, creating a third recurring testing channel above the initial therapy selection and progression monitoring episodes. Burning Rock Biotech released clinical data in September 2023 demonstrating high accuracy of its LungPlasma test for detecting EGFR mutations in early-stage NSCLC patients in China, establishing domestic clinical validation in the Chinese market at the therapy selection application. These are some of the key factors driving revenue growth of the market.

CMS 2025 national payment rates at USD 5,000.00 for Guardant360 CDx and USD 3,500.00 each for FoundationOne Liquid CDx and Signatera create uniform national reimbursement certainty that will meaningfully expand liquid biopsy test ordering volume at community oncology practices previously uncertain about billing under local LCD frameworks. National rates eliminate the geographic access inequities of the prior patchwork where coverage differed by Medicare Administrative Contractor jurisdiction, representing the single most important US policy event for the liquid biopsy market since the original FDA companion diagnostic approvals of Guardant360 CDx and FoundationOne Liquid CDx.

The third driver is the structural development of Asia Pacific liquid biopsy commercial ecosystems that are independent of US FDA approval and CMS reimbursement frameworks, because Asia Pacific markets including China and Japan are building domestic liquid biopsy market infrastructure through NMPA regulatory approvals, insurer coverage policy, and domestic clinical validation studies that generate market growth above the baseline driven by multinational platform adoption at premium academic oncology accounts. Asia Pacific market development works commercially because China's National Medical Products Administration has approved multiple domestic ctDNA panels from Burning Rock Biotech and Singlera that compete at 30 to 50% lower price points than Guardant360 CDx or FoundationOne Liquid CDx, enabling provincial pilot reimbursement programmes that boost domestic uptake at Chinese hospital oncology departments serving the vast majority of China's NSCLC patient population who cannot access USD 5,000.00 international platform testing. Guardant Health expanded its China market presence through its existing partnership with Adicon Holdings, extending Guardant360 circulating tumour DNA monitoring and blood-based epigenomic analyses to the Chinese oncology market through Adicon's established Chinese hospital laboratory distribution network at premium tier-1 academic oncology accounts. Japan's insurer coverage for liquid biopsy when tissue sampling risks complications creates a domestically reimbursed lung cancer liquid biopsy market that is sustained by Japan's high lung cancer incidence rate in elderly male smokers and the preference of Japanese oncologists for non-invasive diagnostic approaches in elderly patients with compromised pulmonary function limiting biopsy tolerability. These are some of the key factors driving revenue growth of the market.

However, the lung cancer liquid biopsy market faces adoption constraints from lower analytical sensitivity versus tissue biopsy for detecting low-frequency somatic mutations in early-stage NSCLC where ctDNA shedding rates are insufficient for confident negative results, requiring reflex tissue biopsy to confirm negative ctDNA findings and limiting the capacity of liquid biopsy to fully replace tissue biopsy in the diagnostic algorithm. Iran-US sanctions following the escalation of the United States-Iran confrontation in late February 2026 affected semiconductor and specialty reagent supply chains for next-generation sequencing instrument components and ctDNA library preparation reagent intermediates sourced through Strait of Hormuz logistics corridors, adding NGS platform manufacturing cost pressure through Q1 and Q2 2026. Reimbursement limitations outside the US and Western Europe restrict liquid biopsy adoption at emerging market oncology centres where out-of-pocket testing costs of USD 500.00 to USD 5,000.00 per test are unaffordable without premium insurance, limiting global penetration below the epidemiological potential suggested by worldwide lung cancer incidence of 2.20 Million annual cases. Physician CGP report interpretation training requirements create adoption barriers at community oncology centres, as the breadth of genomic and epigenomic findings in Guardant360 Liquid CDx requires oncologist familiarity with multiple actionable biomarker categories that is less established at community practices than at academic comprehensive cancer centres. These factors substantially limit lung cancer liquid biopsy market growth over the forecast period.

Based on regional analysis, the lung cancer liquid biopsy market in North America accounted for the largest revenue share in 2025 at approximately 45% of global revenue. The US market drives the regional position through CMS 2025 national payment rates of USD 5,000.00 for Guardant360 CDx and USD 3,500.00 for FoundationOne Liquid CDx, the FDA companion diagnostic approval infrastructure, and the commercial concentration of Guardant Health, Foundation Medicine (Roche), and Natera as the three dominant US lung cancer liquid biopsy providers with the three vendors collectively controlling approximately 60% of US liquid biopsy revenue per commercial analysis. Guardant Health holds over 21% global liquid biopsy market share in 2024 per commercial analysis. The Iran-US sanctions escalation through Q1 and Q2 2026 does not materially disrupt North American liquid biopsy laboratory operations, as Guardant's Palo Alto laboratory and Foundation Medicine's Cambridge laboratory maintain domestic US reagent and sequencing supply chains outside the affected logistics corridors.

The market in Asia Pacific is expected to register the fastest revenue growth rate over the forecast period at approximately 13.45% CAGR. China, Japan, South Korea, and Australia represent the four largest national markets. China's NMPA-approved domestic ctDNA panels from Burning Rock Biotech and Singlera compete at 30 to 50% lower price points than international platforms, developing as a parallel ecosystem with domestic brands dominant in volume at tier-2 and tier-3 hospitals and international brands capturing premium accounts at JCI-accredited tier-1 oncology centres. Japan's insurer coverage for liquid biopsy when tissue sampling risks complications creates a reimbursed domestic market sustained by high lung cancer incidence in elderly male smokers.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, the United Kingdom, and Italy represent the four largest national markets. Grail's CE mark for its Galleri multi-cancer early detection blood test in November 2023 expanded commercial availability across the EU including for high-risk lung cancer patients, with the Galleri NHS pilot in the United Kingdom providing large-scale clinical implementation data. ESMO 2024 consensus statements adding plasma testing for resistance mechanism identification after targeted therapy failure reinforces European clinical guidelines supporting repeat liquid biopsy testing at NSCLC progression.

The markets in Latin America and Middle East and Africa are expected to register moderate revenue growth rates over the forecast period. Brazil and Mexico represent the two largest LatAm markets. Brazil's INCA-affiliated oncology programmes at Sao Paulo and Rio de Janeiro cancer centres are adopting comprehensive liquid biopsy CGP for NSCLC therapy selection in clinical trial settings. Saudi Arabia and UAE represent the primary GCC markets, with JCI-accredited GCC oncology hospitals introducing Guardant360 CDx and FoundationOne Liquid CDx for NSCLC treatment selection at premium private hospital cancer programmes.